Natco Pharma Acquires Remaining 49% Stake in Indonesian Subsidiary for ₹7.7 Crore
Natco Pharma's subsidiary acquired the remaining 49% stake in PT NATCO Lotus Farma for ₹7.7 crore. This brings Natco's total ownership in the Indonesian pharmaceutical subsidiary to 100%. The acquisition was completed via cash consideration.
The acquisition amount of ₹7.7 crore is relatively small compared to Natco Pharma's overall business size, suggesting a limited financial impact on the company.
The acquisition of full ownership in a subsidiary is generally seen as a positive strategic move for consolidating control and potentially increasing future profitability.
Natco Pharma Limited announced that its wholly-owned subsidiary, NATCO Pharma Asia Pte. Ltd., incorporated in Singapore, has acquired the remaining 49% shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. Previously, NATCO held a 51% stake in the Indonesian entity. Following this acquisition, NATCO, along with its subsidiary, now wholly owns 100% of PT NATCO Lotus Farma.
The acquisition was a cash consideration amounting to IDR 14,075,400,000, which is approximately ₹7.7 crore. The target entity, PT NATCO Lotus Farma, operates in the Pharmaceuticals industry and was incorporated on August 28, 2023. Its turnover for the year-to-date September 2025 was IDR 5,073 million (approximately ₹2.7 crore), and for April-March 2025, it was IDR 3,324 million (approximately ₹1.6 crore). No turnover was reported for the fiscal years April-March 2024 and April-March 2023. The acquisition's objective is to achieve full ownership of the Indonesian subsidiary, and it has already been completed with no governmental or regulatory approvals required.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.